TUB-010, a Tub-tag CD30-targeting ADC with improved therapeutic window
Dec. 14, 2022
Researchers from Tubulis GmbH presented preclinical data for a CD30-targeting antibody-drug conjugate (ADC), TUB-010, being developed as a potential anticancer immunotherapy candidate.